• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Ministry of Health, Malaysia and Drugs for Neglected Diseases initiative combine forces to lead the battle against dengue

Malaysia joins to become a partner in a new international alliance led by dengue-endemic countries to search for dengue treatment

Home > Press releases

Ministry of Health, Malaysia and Drugs for Neglected Diseases initiative combine forces to lead the battle against dengue

Malaysia joins to become a partner in a new international alliance led by dengue-endemic countries to search for dengue treatment

Researchers in lab setting
Kuala Lumpur, Malaysia — 29 Apr 2022
  • English
    • English
    • Bahasa Malaysia
    • ไทย
    • العَرَبِية

Malaysian Ministry of Health through Clinical Research Malaysia (CRM) today joined forces with the international non-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) in a collaboration that aims to develop safe, affordable, and effective treatments for dengue fever.

Through this agreement, Malaysia joins a global dengue partnership led by dengue-endemic countries through a South-South collaboration to conduct preclinical studies and clinical trials, aimed at delivering an affordable and accessible treatments within five years.

DNDi and CRM will work together with Malaysia’s leading research institutes such as Institute for Clinical Research (ICR) and Institute for Medical Research (IMR) on joint projects to progress preclinical investigations of potential treatments, test the efficacy of repurposed drug candidates, and implement clinical trials of the most promising ones. At the same time, it will coordinate efforts to help overcome knowledge gaps and expedite clinical research to address unmet needs. The partnership will work together to mobilize resources, share research knowledge, and address financing gaps.

More than 70% of the global dengue burden is in Asia where severe dengue has become a leading cause of hospitalization and death among children and adults in many countries. Malaysia has implemented several vector control strategies to prevent transmission of dengue and control outbreaks. Despite extensive research and development for dengue fever treatments and vaccines, effective solutions for the disease has not been achieved.

‘The Ministry of Health, Malaysia aims to continue on its trajectory by investing in preventive initiatives that will enhance dengue preparedness, towards eradicating the dengue epidemic by 2030. Leading much of these efforts, MOH is keen to continue its existing partnership with DNDi, that have led exemplary work in having established safe, affordable, and effective treatment of hepatitis C, garnered through collaborative efforts between developing nations, including Malaysia,’ said YB Khairy Jamaluddin, Minister of Health, Malaysia.

‘DNDi is proud to have Malaysia on board. It is exciting to see dengue-endemic countries unite to pool collective knowledge and expertise in addressing the need for safe and effective dengue treatments that are affordable and accessible for all patients,’ said Jean-Michel Piedagnel, Director, DNDi South-East Asia Regional Office.

About Clinical Research Malaysia (CRM) 

Established by Malaysian Ministry of Health in 2012, Clinical Research Malaysia exists to advance global health solutions for a brighter, more hopeful future for the people by providing speedy and reliable end-to-end clinical research support for quality studies. CRM’s innate understanding of the local clinical research landscape with the international standards of operations coupled with fundamental backing of the government ministries provides the organisation an incomparable advantage to work with partners from the nascent stages of development to materialisation of the end product, in order to deliver better treatment and high-skilled job opportunities. https://clinicalresearch.my/

About DNDi

A not-for-profit research and development organization, DNDi  works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, and hepatitis C. DNDi is also coordinating the ANTICOV clinical trial to find treatments for mild-to-moderate COVID-19 cases in Africa. Since its inception in 2003, DNDi  has delivered nine new treatments to date, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness. dndi.org

Media contacts 

DNDi
Molly Jagpal
mjagpal@dndi.org
+6012-546-8362

Clinical Research Malaysia (CRM)
Asha Thanabalan
asha@clinicalresearch.my   
+6012- 364 8043

Photo credit: Luke Duggleby-DNDi

Partnership Dengue Asia Malaysia

Read, watch, share

Loading...
Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Screening activities in village in Guinea
News
25 Apr 2025

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

Woman walking in a laboratory
Press releases
23 Apr 2025

DNDi welcomes GHIT support for new project with three Japanese universities to find drug candidates for Chagas disease

Stories
16 Apr 2025

Drug discovery explained: Chagas – How to prove treatments work?

Statements
16 Apr 2025

Statement from the Drugs for Neglected Diseases initiative (DNDi) on the conclusion of WHO Pandemic Agreement negotiations

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License